Reporting on the companies, capacity, raw materials and trade shaping the peptide supply chain.
Asymchem expects stronger utilization of its peptide manufacturing capacity in 2027, with qualification-stage deliveries concentrated in late 2026. The outlook suggests growing activity across its existing production platform, although further expansion remains dependent on orders.
DuPont is expanding its peptide-purification portfolio with new C8 and C18 chromatography media, giving manufacturers additional options for downstream processing as GLP-1 production scales.
Sanofi has moved ahead with a major investment in European insulin API manufacturing, but the new Frankfurt facility is not expected to reach full production until 2032. The project strengthens Sanofi's captive supply network rather than adding capacity available to outside buyers.
China's peptide-synthesis resin supply could gain a new domestic producer, but Zhengguang's proposed 250-tonne-per-year biopharma-resin project remains some distance from commercial production. The total capacity also covers other resin applications.
The provisional result advances Samsung’s proposed acquisition of an established peptide API manufacturing platform. Ownership transfer still depends on confirmation and remaining conditions; no additional manufacturing capacity is established.
The November target brings a previously disclosed peptide expansion closer to a production milestone. JYMed's ten-tonne annual capacity figure is a prospective total for its Hubei base, not ten tonnes of new output or supply already available to buyers.
Washington is looking upstream in the peptide supply chain. Inquiry explicitly identifies PAAs and peptide fragments as starting materials for oxytocin and vasopressin, potentially putting upstream peptide suppliers in the frame for future federal procurement and manufacturing support.
Shengnuo’s US peptide API business has hit a regulatory roadblock. The company has suspended US shipments after its manufacturing subsidiary was placed on an FDA import alert.
Peptide manufacturing has a TFA problem. Claros’ pilot at Bachem points to a potential way to destroy TFA in wastewater without changing the underlying synthesis process. The next test is whether the technology can work economically at commercial scale.
CordenPharma’s more than $200 million North Augusta expansion will add upstream peptide synthesis capacity alongside its existing downstream operations in Colorado.
Neuland’s 7,000 L peptide module is now operational, while a proposed second module of up to 18,000 L remains dependent on customer-defined requirements.
Amylyx is securing multiple sources of prospective avexitide supply, with a $30 million PolyPeptide reservation fee revealing the cost of manufacturing access.